|

7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)

RECRUITINGSponsored by University of Missouri-Columbia
Actively Recruiting
SponsorUniversity of Missouri-Columbia
Started2025-11-01
Est. completion2027-09
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site

Summary

Comparison of a 7t MRI to standard of care 1.5t/3t MRI scans to determine if earlier detection of brain metastases are possible on a 7t.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patient must have a histologically confirmed diagnosis of small-cell lung cancer (SCLC). • Patient must have an MRI of the brain, performed within 4 weeks prior to consent, documenting no evidence of brain metastases or leptomeningeal disease.
* Patient also must not have a history of brain metastases or leptomeningeal disease.
* Patient must refuse PCI and agree to surveillance with brain MRI scans (1.5T/3T).
* Patient must be ≥ 18 years of age.
* Patient must have ECOG Performance Status of 0-2
* Patients must be able to tolerate the 7T MRI

Exclusion Criteria:

* Patient must not have a contraindication to an MRI, such as implanted metal devices or foreign bodies.
* Patient must not have a contraindication to gadolinium contrast administration during MR imaging.
* Patient must not have other metastatic malignancies requiring current active treatment.
* Pregnant patients are excluded. Pregnancy status will be confirmed verbally.

Conditions4

Brain MetastasesCancerLung CancerSmall Cell Lung Cancer

Locations1 site

University of Missouri
Columbia, Missouri, 65212
Brooke McDaniel(573) 882-7440mcdanielbl@health.missouri.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.